Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab’s efficacy in vitro?

References

• BursteinHJThe distinctive nature of HER2-positive breast cancersN Engl J Med20053531652165416236735
   PubMed Web of Science ®Google Scholar
• KlapperLGlatheSVaismanNThe ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factorsProc Natl Acad Sci U S A1999964995500010220407
   PubMed Web of Science ®Google Scholar
• CitriASkariaKBYardenYThe deaf and the dumb: the biology of ErbB-2 and ErbB-3Exp Cell Res2003284546512648465
   PubMed Web of Science ®Google Scholar
• RossJSSlodkowskaEASymmansWFPusztaiLRavdinPMHortobagyiGNThe HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineOncologist20091432036819346299
   PubMed Web of Science ®Google Scholar
• TzaharEWatermanHChenXA hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factorMol Cell Biol199616527653878816440
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNature Rev Mol Cell Biol2001212713711252954
   PubMed Web of Science ®Google Scholar
• LeahyBDJStructure and function of the epidermal growth factor (EGF/ErbB) family of receptorsAdv Protein Chem20046812715500857
   PubMedGoogle Scholar
• HudisCATrastuzumab – mechanism of action and use in clinical practiceN Engl J Med2007357395117611206
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNECardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialJ Clin Oncol2008261231123818250349
   PubMed Web of Science ®Google Scholar
• KruserTJWheelerDLMechanisms of resistance to HER family targeting antibodiesExp Cell Res20103161083110020064507
   PubMed Web of Science ®Google Scholar
• MountziosGSanoudouDSyrigosKNClinical pharmacogenetics in oncology: the paradigm of molecular targeted therapiesCurr Pharm Des2010162184219320459386
   PubMed Web of Science ®Google Scholar
• TaiWMahatoRChengKThe role of HER2 in cancer therapy and targeted drug deliveryJ Control Release201014626427520385184
   PubMed Web of Science ®Google Scholar
• LowerEEGlassEBlauRHarmanSHER-2/neu expression in primary and metastatic breast cancerBreast Cancer Res Treat200911330130618273700
   PubMed Web of Science ®Google Scholar
• NahtaRYuDHungMCHortobagyiGNEstevaFJMechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancerNat Clin Pract Oncol2006326928016683005
   PubMedGoogle Scholar
• FriedländerEBarokMSzöllosiJVerebGErbB-directed immunotherapy: antibodies in current practice and promising new agentsImmunol Lett200811612614018201769
   PubMed Web of Science ®Google Scholar
• CallahanRHurvitzSHuman epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent diseaseCurr Opin Obstet Gynecol201123374321500375
   PubMed Web of Science ®Google Scholar
• WeigeltBGeyerFCReis-FilhoJSHistological types of breast cancer: how special are they?Mol Oncol2010419220820452298
   PubMed Web of Science ®Google Scholar
• GewirtzDAA critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochem Pharmacol19995772774110075079
   PubMed Web of Science ®Google Scholar
• CampiglioMSomenziGOlgiatiCRole of proliferation in HER2 status predicted response to doxorubicinInt J Cancer200310556857312712452
   PubMed Web of Science ®Google Scholar
• DangCFornierMSugarmanSThe safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancerJ Clin Oncol2008261216122218323546
   PubMed Web of Science ®Google Scholar
• FerencPSolárPMikešJKoval’JFedoročkoPBreast cancer and current therapeutic approaches: from radiation to photodynamic therapyGunduzMGunduzEBreast Cancer: Current and Alternative Therapeutic ModalitiesRijeka, CroatiaInTech20116387
   Google Scholar
• DeboerCMeulmanPAWnukRJPetersonDHGeldanamycin, a new antibioticJ Antibiot1970234424475459626
   PubMed Web of Science ®Google Scholar
• ToftDORecent advances in the study of hsp90 structure and mechanism of actionTrends Endocrinol Metab1998923824318406275
   PubMed Web of Science ®Google Scholar
• NeckersLSchulteTWMimnaughEGeldanamycin as a potential anti-cancer agent: its molecular target and biochemical activityInvest New Drugs19991736137310759403
   PubMed Web of Science ®Google Scholar
• BishtKSBradburyCMMattsonDGeldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicityCancer Res2003638984899514695217
   PubMed Web of Science ®Google Scholar
• MussHBThorADBerryDAc-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancerN Engl J Med1994330126012667908410
   PubMed Web of Science ®Google Scholar
• PetitTBorelCGhnassiaJNew therapeutic targets in the intrinsic apoptotic pathway in neuroblastomaClin Cancer Res200171577158111410493
   PubMed Web of Science ®Google Scholar
• WangSKonorevEAKotamrajuSJosephJKalivendiSKalyanaramanBDoxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanismsJ Biol Chem2004279255352554315054096
   PubMed Web of Science ®Google Scholar
• GamenSAnelaAPérez-GalánPDoxorubicin treatment activates a Z-VAD-sensitive caspase, which causes Δψm loss, caspase-9 activity, and apoptosis in Jurkat cellsExp Cell Res200025822323510912804
   PubMed Web of Science ®Google Scholar
• Bar-OnOShapiraMHershkoDDDifferential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cellsAnticancer Drugs2007181113112117893511
   PubMed Web of Science ®Google Scholar
• PotterAJGollahonKAPalancaBJAFlow cytometric analysis of the cell cycle phase specificity of DNA damage induced by radiation, hydrogen peroxide and doxorubicinCarcinogenesis20022338940111895853
   PubMed Web of Science ®Google Scholar
• PegramMHsuSLewisGInhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene1999182241225110327070
   PubMed Web of Science ®Google Scholar
• BaselgaJNortonLAlbanellJKimYMendelsohnJRecombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograftsCancer Res199858282528319661897
   PubMed Web of Science ®Google Scholar
• HosteinIRobertsonDDistefanoFWorkmanPClarkePAInhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosisCancer Res2001614003400911358818
   PubMed Web of Science ®Google Scholar
• HelmbrechtKZeiseERensingLChaperones in cell cycle regulation and mitogenic signal transduction: a reviewCell Prolif20003334136511101008
   PubMed Web of Science ®Google Scholar
• ShimamuraTLowellAMEngelmanJAShapiroGIEpidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycinsCancer Res2005656401640816024644
   PubMed Web of Science ®Google Scholar
• KimSKangJHuWEversBMChungDHGeldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomasInt J Cancer200310335235912471618
   PubMed Web of Science ®Google Scholar
• ParkJYehMWWongMGThe heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell linesJ Endocrinol Metab20038833463353
   PubMed Web of Science ®Google Scholar
• GeorgakisGVLiYYounesAThe heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9Br J Haematol2006135687116925576
   PubMed Web of Science ®Google Scholar
• AligueRAkhavan-NiakHRussellPA role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90EMBO J1994136099601067813446
   PubMed Web of Science ®Google Scholar
• StepanovaLLengXParkerSBHarperJ WMammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4Genes Dev199610149115028666233
   PubMed Web of Science ®Google Scholar